NE3107 in Adults With Neurological Symptoms of Long COVID
NCT ID: NCT06847191
Last Updated: 2025-09-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
208 participants
INTERVENTIONAL
2025-04-29
2026-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Researchers will compare NE3107 to a placebo (a look-alike substance that contains no drug) to see if NE3107 works to treat neurocognitive and fatigue symptoms of long COVID.
Participants will:
* Take NE3107 or a placebo twice daily for 84 days
* Visit the clinic 5 times for checkups and tests and have a follow up phone call
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 3 Study of NE3107 in Probable Alzheimer's Disease
NCT04669028
REVERSE-Long COVID-19 With Baricitinib Study
NCT05858515
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
NCT01492374
Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women
NCT01532115
The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease
NCT00006187
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NE3107
One 20 mg capsule containing NE3107 taken by mouth twice daily (BID)
NE3107
20 mg Capsule
Placebo
One 20 mg capsule containing placebo taken by mouth twice daily (BID)
Placebo
placebo capsule
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NE3107
20 mg Capsule
Placebo
placebo capsule
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosed with Long COVID with symptoms of fatigue and brain fog for at least 3 months
* agree to use birth control measures
* provide voluntary consent
* willing to allow blood collection
* pass all screening tests and procedures
Exclusion Criteria
* previous admission to the intensive care unit for COVID-19
* medical history of major mental or physical illness prior to COVID-19 infection
18 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BioVie Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trial Site
San Francisco, California, United States
University of Colorado
Aurora, Colorado, United States
Clinical Trial Site
Jacksonville, Florida, United States
Centricity Research
Columbus, Georgia, United States
Illinois Research Network University of Illinois at Chicago
Chicago, Illinois, United States
University of Iowa
Iowa City, Iowa, United States
Norton Infectious Disease Institute
Louisville, Kentucky, United States
Jadestone Clinical Research
Silver Spring, Maryland, United States
Clinical Trial Site
Farmington Hills, Michigan, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Zenos Clinical Research
Dallas, Texas, United States
University of Texas health Science Center at San Antonio
San Antonio, Texas, United States
West Virginia University
Morgantown, West Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Grayson Scott
Role: primary
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CDMRP-PR230631
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
NE3107-LC-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.